<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327403</url>
  </required_header>
  <id_info>
    <org_study_id>B7-1</org_study_id>
    <nct_id>NCT02327403</nct_id>
  </id_info>
  <brief_title>Belatacept Conversion in Proteinuric Kidney Transplant Recipients</brief_title>
  <official_title>The B7-1 Study&quot;: Belatacept Conversion in Proteinuric Renal Transplant Recipients: an Interventional Multi-Center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Proteinuria develops in about 30% of kidney transplant recipients and is a strong
      predictor of graft loss. The amount of proteinuria has a direct correlation with the risk of
      graft failure. Novel therapies are urgently needed to reduce proteinuria and prevent graft
      loss in transplant recipients, since ACE inhibitors carry a number of limitations in the
      transplant setting, including significant reduction in renal function, anemia and
      hyperkalemia.

      Preliminary data: B7-1 is expressed at significant levels in about 10% of kidney allograft
      biopsies with predominance in patients with proteinuria.

      Hypothesis: We hypothesize that B7-1 targeting therapy may reduce proteinuria and improve
      graft survival in proteinuric transplant recipients that have B7-1 staining on allografts. In
      addition, the absence of CNI nephrotoxicity and the potential protective effect of Belatacept
      on DSA production may be of benefit in this subset of transplant patients.

      Objectives:

      Primary: Determine the effect of Belatacept conversion in reducing proteinuria by 25% at 12
      months in renal transplant recipients (≥1gram/d) that are either B7-1-positive or negative on
      kidney biopsy.

      Secondary: Assess the effect of Belatacept conversion in the percent change of renal function
      from baseline to 12 months; donor-specific anti-HLA antibodies presence and intensity (MFI);
      correlation of B7-1 positivity on immunofluorescence on biopsy with B7-1-expression in urine
      extracellular vesicles; adverse events; acute rejection episodes; blood pressure control; new
      onset diabetes; hyperlipidemia; graft survival; and patient survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 36 patients will be recruited.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Proteinuria by 25%</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change of renal function (Creatinine in mg/dl and eGFR in ml/min)</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number and mean-fluoroscence intensity of donor-specific anti-HLA antibodies (DSA)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of B7-1 positivity on immunofluorescence on biopsy (grade 1-3) with B7-1-expression in urine extracellular vesicles (mean-fluoroscence intensity)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection episodes</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood pressure measurement (mm Hg)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset diabetes</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperlipidemia</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>B7-1 positivity on kidney allograft biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Belatacept conversion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B7-1 negativity on kidney allograft biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Belatacept conversion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.</description>
    <arm_group_label>B7-1 positivity on kidney allograft biopsy</arm_group_label>
    <arm_group_label>B7-1 negativity on kidney allograft biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adult kidney transplant recipients older than 18 years old

          2. eGFR ≥30 ml/min

          3. ≥6 months after transplantation

          4. Proteinuria ≥1 gram/day in spot urine protein/creatinine ratio

          5. Ability to provide written informed consent for the study.

          6. Maintenance immunosuppression of CNI (cyclosporine or tacrolimus), antiproliferative
             agent (azathioprine, MMF or MPA) with either steroids or not.

        Exclusion Criteria:

          1. Age &lt;18 years

          2. eGFR&lt;30 ml/min

          3. active acute cellular rejection (ACR; higher than borderline) or ACR in the previous 6
             months; active acute antibody-mediated rejection

          4. recurrent FSGS

          5. EBV IgG negative

          6. patient on mTOR inhibitor (e.g. Everolimus, Sirolimus)

          7. patient only on CNI (cyclosporine or tacrolimus) and steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo V Riella, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <last_update_submitted>November 4, 2017</last_update_submitted>
  <last_update_submitted_qc>November 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Leonardo V. Riella, MD PhD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Proteinuria</keyword>
  <keyword>Kidney transplantation</keyword>
  <keyword>Allograft dysfunction</keyword>
  <keyword>B7-1</keyword>
  <keyword>Belatacept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

